Pomerantz Law Firm Initiates Class Action Lawsuit Against Chemours Company

On October 15, 2026, Pomerantz LLP announced the initiation of a class action lawsuit targeting The Chemours Company (NYSE: CC) and specific corporate officers. This significant legal action was lodged in the United States District Court for the District of Delaware, classified under docket number 26-cv-01299. The lawsuit is on behalf of all individuals and entities that purchased Chemours securities between February 20, 2026, and August 4, 2026.

The plaintiffs seek to recover damages stemming from alleged violations of federal securities laws, specifically invoking Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Investors who acquired Chemours securities during this classified period are urged to consider petitioning the Court before the deadline on December 7, 2026, to be appointed as Lead Plaintiff for the class.

Those interested can obtain a copy of the Complaint from Pomerantz's website or reach out to Danielle Peyton via the provided contact details, including her email and phone number. When contacting, inquiry parties are advised to include their contact information and the number of shares purchased to facilitate the response process.

Chemours is a major supplier of industrial and specialty chemicals, focusing on various sectors, including refrigeration and air conditioning solutions. One of its notable products is Opteon™, which boasts a 'near-zero ozone-depletion footprint' and is developed under its Thermal Specialty Solutions segment. The company’s business operations and growth claims were purportedly bolstered by their alleged compliance with the American Innovation and Manufacturing Act (U.S. AIM Act), ratified by Congress in December 2020, which aims to reduce climate change impacts by regulating refrigerant transitions.

Throughout the class period, the complaint asserts that Chemours and its executives misled investors about the demand and performance metrics of their Opteon products. The allegations highlight that there was a significant inflation in reported aftermarket demand, suggesting a contrast to the actual declining sales and operational capacities. These misleading declarations purportedly led to unreliable financial forecasts for the fiscal year 2026, resulting in misrepresentations during critical reporting periods.

The turning point came on August 4, 2026, when Chemours disclosed its financial performance for the second quarter of that year. The Company lowered its adjusted EBITDA projections from an earlier range of $800 million to $900 million to a revised estimate of $775 million to $825 million. Compounding the situation, the management admitted on an earnings call that surplus inventory levels were negatively affecting market dynamics, admitting that approximately $65 million of aftermarket sales should have been allocated differently, implying miscalculations from prior strategies impacting current financial health.

In the wake of this announcement, Chemours’ stock suffered a considerable drop, witnessing a dip of $3.34 per share (equating to an 18.63% decline) on August 5, closing at $14.59 a share.

Pomerantz LLP is recognized as a leading firm in securities and corporate class litigation, boasting a track record that spans over 85 years, during which it has amassed billions in damage recoveries for its clients. The firm's founder, the late Abraham L. Pomerantz, was a pioneer in class action law, and today the firm continues to advocate for justice and recovery for victims of securities fraud and corporate failures.
For more details regarding this emerging class action lawsuit or to explore participation options, stakeholders are encouraged to visit the Pomerantz website or directly contact the firm.

Legal representation within the Pomerantz LLP is vital for those impacted by this case, as the firm brings wealth of experience and knowledge in navigating these complex legal waters. Investors affected by Chemours' representation in the marketplace now have a pathway to seek restitution for perceived losses that occurred under the alleged corporate misconduct.